Nivolumab and ipilipimab for renal cell cancer – pro
A phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. This regimen is now supported by NCCN and The Food and Drug Administration has approved the use of Opdivo (nivolumab) for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. teh combinaiton with Yervoy si also FDA approved.
Robert J. Motzer, M.D., Nizar M. Tannir, M.D. et al, Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018; 378:1277-1290